Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
AssigneeEli Lilly and Company
InventorsFatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, William Terry Johnson, Vignati Louis
Life of this patent
Estimating the term…
Abstract
Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associated with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
Claims34
A method of treating non-insulin dependent diabetes mellitus comprising co-administering:
- a) an effective dosage of a GLP-1 peptide agonist;
- and
- b) an effective dosage of pioglitazone or rosiglitazone.
Dependencies are inferred from the claim text.